The mature model with a 15-year projection showed that the life expectancy for patients with sensitising EGFR mutations stage III unresectable NSCLC in the USA and China, post-chemoradiotherapy and without disease progression increased by 0.45 LYs (5.40 months) and 0.39 LYs (4.68 months) respectively with osimertinib consolidation therapy relative to placebo. Here, EGFR is linked to non-small cell lung carcinoma.